The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.
|Videos|April 13, 2017
Biomarkers Could Predict Bladder Cancer Progression
Author(s)Emil Christensen
This video examines a study that used liquid biopsies to monitor disease progression in patients with bladder cancer.
Advertisement
In this video, Emil Christensen, a researcher at Aarhus University Hospital in Denmark, discusses a study that used liquid biopsies to monitor disease progression in bladder cancer patients.
The study examined the feasibility and utility of tracking FGFR3 and PIK3CA hotspot mutations in patients’ urine and plasma. Two patient cohorts were studied: one included patients with non–muscle invasive disease, the other included those with muscle-invasive disease.
The results of the
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
2
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
3
Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care
4
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
5